| Name | Title | Contact Details |
|---|
DNoA also offers a complete range of third party administration services for multiple dental products, including Dental Preferred Provider Organization (DPPO), Dental Health Maintenance Organization (DHMO) and Indemnity Insurance (fee-for-service).
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. We do this by developing cost-effective medical technologies that save and improve lives. St. Jude Medical provides safe and effective technologies that are of the highest quality—and that quality is something we take very seriously because we know patients around the world rely on our technologies. Our approximately 18,000 employees are passionate in their commitment to this priority. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, remote monitoring systems, cardiac mapping and visualization systems, catheter-based ablation devices, vascular closure devices, structural heart products, spinal cord stimulation, peripheral nerve stimulation and deep brain stimulation devices. All qualified applicants will receive consideration for employment without regard to race, color, creed, religion, sex, national origin, marital status, age, citizenship, protected veteran status, sexual orientation, gender identity and/or gender expression, status with respect to public assistance, or disability status.
Arcadia Resources, Inc. is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
ProStat is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.